Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allogene Therapeutics, Inc.
  6. News
  7. Summary
    ALLO   US0197701065

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Real-time Estimate Cboe BZX  -  12:12 2022-06-28 pm EDT
11.44 USD   -2.26%
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

B. Riley Lowers Allogene Therapeutics' PT to $21 from $30 on Heels of Regulatory Requirement for ALLO-647 Lymphodepleting Antibody, Keeps Buy Rating

02/28/2022 | 09:42am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ALLOGENE THERAPEUTICS, INC.
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2500 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000E Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 3000 Growth Index
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell Small Cap Comp Growth In..
CI
06/24ALLOGENE THERAPEUTICS, INC.(NASDAQGS : ALLO) dropped from Russell 2000 Growth Index
CI
06/23INSIDER SELL : Allogene Therapeutics
MT
06/17ALLOGENE THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders, Financi..
AQ
06/13TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Goldman Sachs 43rd Annual Global Heal..
CI
06/08Allogene Therapeutics Shares Rise 9% After FDA Approves Trial for Lymphoma
DJ
06/08Allogene's Potential Cancer Treatment Gets FDA's Regenerative Medicine Advanced Therapy..
MT
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,12 M - -
Net income 2022 -367 M - -
Net cash 2022 326 M - -
P/E ratio 2022 -4,54x
Yield 2022 -
Capitalization 1 680 M 1 680 M -
EV / Sales 2022 11 138x
EV / Sales 2023 253x
Nbr of Employees 334
Free-Float 55,8%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 11,70 $
Average target price 25,71 $
Spread / Average Target 120%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-17.69%1 763
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-12.75%44 742
BIONTECH SE-48.01%32 574